Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial
- 1 June 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (6) , 1441-1447
Abstract
Recent evidence suggests that reaching the lowest achievable levels of testosterone with androgen deprivation therapy delays disease progression and increases overall survival in men with advanced prostate cancer. The aim of this analysis was to compare posttreatment serum testosterone levels between patients undergoing subcapsular orchiectomy and patients treated with the luteinizing hormone-releasing hormone agonist triptorelin. In this randomized clinical trial we included 58 consecutive hormone naïve men diagnosed with advanced prostate cancer at Herlev and Gentofte University Hospital, Herlev, Denmark from September 2013 to March 2015. Followup was 48 weeks. Participants were randomly assigned 1:1 to subcapsular orchiectomy or triptorelin 22.5 mg given as 24-week depot injections. Androgen status was measured by liquid chromatography-tandem mass spectrometry prior to treatment and after 12, 24 and 48 weeks. Between group differences in achieved hormone levels were analyzed by longitudinal Tobit regression. Triptorelin injections resulted in 29% lower testosterone levels (95% CI 17.2-41.7) compared to subcapsular orchiectomy (p <0.001). A significantly higher proportion of men receiving triptorelin had testosterone levels less than 20 ng/dl at 12 and 48 weeks compared to men undergoing orchiectomy (97% vs 79% and 100% vs 87%, respectively, p <0.05). There was no detectable difference in the adrenal androgen reduction between the treatment groups. The use of 24-week depot triptorelin injections results in significantly lower testosterone levels compared to subcapsular orchiectomy. To our knowledge this is the first randomized study to demonstrate a difference in treatment effect between surgical and medical castration on testosterone levels.Keywords
This publication has 30 references indexed in Scilit:
- Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate CancerClinical Genitourinary Cancer, 2013
- Luteinizing Hormone (LH)–Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal GlandsJournal of Andrology, 2012
- Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass SpectrometryJournal of Urology, 2012
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- Effect of luteinizing hormone on the steroidogenic pathway in prostate cancerThe Prostate, 2010
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate CancerJournal of Urology, 2006
- BicalutamideClinical Pharmacokinetics, 2004
- Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic CarcinomaBritish Journal of Urology, 1991
- RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMAThe Lancet, 1985